决策曲线分析的报告与解读:研究者指南
本文为决策曲线分析(DCA)的解读与报告提供建议,通过3616例患者数据构建高级别前列腺癌风险模型示例,说明风险阈值、净获益(NB)、默认策略及检验权衡等概念,并给出何时采用模型及如何评估额外成本的解读框架。
要点
- DCA通过净获益评估模型在不同风险阈值下的决策效用。
- 首先判断模型是否在所有合理阈值上优于其他策略。
- 若模型有额外成本,需用检验权衡判断净获益增量是否值得。
核心结论
- 所提指南有助于研究者理解DCA并改进其应用与报告。
研究设计与样本
- 非正式综述泌尿外科文献以了解研究者对DCA的理解,并用3616例患者数据构建高级别前列腺癌风险模型进行示例。
主要发现
- 基础模型包含前列腺特异性抗原和直肠指检,扩展模型增加两个基于经直肠超声(TRUS)的预测因子。
- 在案例研究中,加入TRUS使净获益提高0.0114,相当于每100例患者多检出1.1例高级别前列腺癌。
- 若接受对88例患者进行TRUS以多检出1例高级别前列腺癌,或对10例患者进行TRUS以避免1次不必要活检,则加入TRUS是值得的。
关键数值与推荐
- 首先确定模型是否在所有合理风险阈值范围内优于所有其他策略。
- 若模型有重要额外成本,需获取检验权衡以检查净获益增量是否值得额外成本。
临床怎么用
- 使用DCA时先比较模型与默认策略(全部治疗、全不治疗)及其他策略的净获益。
- 结合检验权衡评估模型额外成本是否可接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Urologists regularly develop clinical risk prediction models to support clinical decisions. In contrast to traditional performance measures, decision curve analysis (DCA) can assess the utility of models for decision making. DCA plots net benefit (NB) at a range of clinically reasonable risk thresholds. OBJECTIVE: To provide recommendations on interpreting and reporting DCA when evaluating prediction models. EVIDENCE ACQUISITION: We informally reviewed the urological literature to determine investigators' understanding of DCA. To illustrate, we use data from 3616 patients to develop risk models for high-grade prostate cancer (n=313, 9%) to decide who should undergo a biopsy. The baseline model includes prostate-specific antigen and digital rectal examination; the extended model adds two predictors based on transrectal ultrasound (TRUS). EVIDENCE SYNTHESIS: We explain risk thresholds, NB, default strategies (treat all, treat no one), and test tradeoff. To use DCA, first determine whether a model is superior to all other strategies across the range of reasonable risk thresholds. If so, that model appears to improve decisions irrespective of threshold. Second, consider if there are important extra costs to using the model. If so, obtain the test tradeoff to check whether the increase in NB versus the best other strategy is worth the additional cost. In our case study, addition of TRUS improved NB by 0.0114, equivalent to 1.1 more detected high-grade prostate cancers per 100 patients. Hence, adding TRUS would be worthwhile if we accept subjecting 88 patients to TRUS to find one additional high-grade prostate cancer or, alternatively, subjecting 10 patients to TRUS to avoid one unnecessary biopsy. CONCLUSIONS: The proposed guidelines can help researchers understand DCA and improve application and reporting. PATIENT SUMMARY: Decision curve analysis can identify risk models that can help us make better clinical decisions. We illustrate appropriate reporting and interpretation of decision curve analysis.
引用
- Van Calster B, Wynants L, Verbeek JFM, et al. Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol. 2018. PMID: 30241973. doi:10.1016/j.eururo.2018.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。